Genetic Determinants of Thiazide-Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances - A Genome-Wide Evaluation of the UK Biobank.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
10
08
2023
accepted:
12
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Thiazide diuretics, widely used in hypertension, cause a variety of adverse reactions, including hyperglycemia, hyperuricemia, and electrolyte abnormalities. In this study, we aimed to identify genetic variants that interact with thiazide-use to increase the risk of these adverse reactions. Using UK Biobank data, we first performed genomewide variance quantitative trait locus (vQTL) analysis of ~ 6.2 million SNPs on 95,493 unrelated hypertensive White British participants (24,313 on self-reported bendroflumethiazide treatment at recruitment) for 2 blood (glucose and urate) and 2 urine (potassium and sodium) biomarkers. Second, we conducted direct gene-environment interaction (GEI) tests on the significant (P < 2.5 × 10
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/V033867/1
Pays : United Kingdom
Informations de copyright
© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet 396, 1204-1222 (2020).
Zhou, B., Perel, P., Mensah, G.A. & Ezzati, M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat. Rev. Cardiol. 18, 785-802 (2021).
Mills, K.T. et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134, 441-450 (2016).
Lawes, C.M., Vander Hoorn, S., Rodgers, A. & International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371, 1513-1518 (2008).
Williams, B. et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021-3104 (2018).
Freis, E.D., Wanko, A., Wilson, I.M. & Parrish, A.E. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. JAMA 166, 137-140 (1958).
Nadal, J., Channavajjhala, S.K., Jia, W., Clayton, J., Hall, I.P. & Glover, M. Clinical and molecular features of thiazide-induced hyponatremia. Curr. Hypertens. Rep. 20, 31 (2018).
Thomopoulos, C., Parati, G. & Zanchetti, A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J. Hypertens. 33, 195-211 (2015).
McNally, R.J., Morselli, F., Farukh, B., Chowienczyk, P.J. & Faconti, L. A review of the prescribing trend of thiazide-type and thiazide-like diuretics in hypertension: a UK perspective. Br. J. Clin. Pharmacol. 85, 2707-2713 (2019).
Malki, M.A., Dawed, A.Y., Haywood, C., Doney, A. & Pearson, E.R. Utilizing large electronic medical Record data sets to identify novel drug-gene interactions for commonly used drugs. Clin. Pharmacol. Ther. 110, 816-825 (2021).
Glover, M., Zuber, A.M. & O'Shaughnessy, K.M. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc. Ther. 29, 68-76 (2011).
Ferguson, L.D., McKay, G. & Fisher, M. Bendroflumethiazide. Pract. Diab. 30, 340-341 (2013).
Arampatzis, S. et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis. BMC Med. 11, 83 (2013).
Sinnott-Armstrong, N. et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat. Genet. 53, 185-194 (2021).
Sollis, E. et al. The NHGRI-EBI GWAS catalog: knowledgebase and deposition resource. Nucleic Acids Res. 51, D977-D985 (2023).
Manuck, S.B. & McCaffery, J.M. Gene-environment interaction. Annu. Rev. Psychol. 65, 41-70 (2014).
McAdams-DeMarco, M.A. et al. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Ann. Rheum. Dis. 72, 701-706 (2013).
Narang, R.K. et al. Do serum urate-associated genetic variants influence gout risk in people taking diuretics? Analysis of the UK Biobank. J. Rheumatol. 47, 1704-1711 (2020).
Wang, H. et al. Genotype-by-environment interactions inferred from genetic effects on phenotypic variability in the UK Biobank. Sci. Adv. 5, eaaw3538 (2019).
Clark, R. et al. Education interacts with genetic variants near GJD2, RBFOX1, LAMA2, KCNQ5 and LRRC4C to confer susceptibility to myopia. PLoS Genet. 18, e1010478 (2022).
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203-209 (2018).
Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
Chaplin, M., Kirkham, J.J., Dwan, K., Sloan, D.J., Davies, G. & Jorgensen, A.L. STrengthening the reporting of Pharmacogenetic studies: development of the STROPS guideline. PLoS Med. 17, e1003344 (2020).
Benchimol, E.I. et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 12, e1001885 (2015).
Fry, D., Almond, R., Moffat, S., Gordon, M. & Singh, P. UK Biobank biomarker project - companion document to accompany serum biomarker data. Version 1.0. In: Showcase UB, editor.; 1-16 (2019).
Fry, D., Almond, R., Gordon, M. & Moffat, S. UK Biobank biomarker project - details of assays and quality control information for the urinary biomarker data Version 1.0. In: Showcase UB, editor. pp. 1-8 (2016).
UK Biobank. Biomarker assay quality procedures: approaches used to minimise systematic and random errors (and the wider epidemiological implications). Version 1.2. In: Biobank U, editor. pp. 1-25 (2019).
Moore, C.M., Jacobson, S.A. & Fingerlin, T.E. Power and sample size calculations for genetic association studies in the presence of genetic model misspecification. Hum. Hered. 84, 256-271 (2019).
Harrell, F.E. rms: Regression Modeling Strategies. R package version 5.1-3.1 https://CRAN.R-project.org/package=rms (2019). Accessed August 27, 2020.
Harrell, F.E. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis 2nd edn. (Springer, New York, NY, 2015).
van Buuren, S. & Groothuis-Oudshoorn, K. Mice: multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1-67 (2011).
Zhang, F. et al. OSCA: a tool for omic-data-based complex trait analysis. Genome Biol. 20, 107 (2019).
Chang, C.C., Chow, C.C., Tellier, L.C.A.M., Vattikuti, S., Purcell, S.M. & Lee, J.J. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
Wu, Y., Zheng, Z., Visscher, P.M. & Yang, J. Quantifying the mapping precision of genome-wide association studies using whole-genome sequencing data. Genome Biol. 18, 86 (2017).
Pulit, S.L., de With, S.A. & de Bakker, P.I. Resetting the bar: statistical significance in whole-genome sequencing-based association studies of global populations. Genet. Epidemiol. 41, 145-151 (2017).
Turner, S. Qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. J. Open Source Softw. 3, 731 (2018).
Nebert, D.W. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur. J. Pharmacol. 410, 107-120 (2000).
Westerman, K.E. et al. Variance-quantitative trait loci enable systematic discovery of gene-environment interactions for cardiometabolic serum biomarkers. Nat. Commun. 13, 3993 (2022).
Hall, J.J., Eurich, D.T., Nagy, D., Tjosvold, L. & Gamble, J.M. Thiazide diuretic-induced change in fasting plasma glucose: a meta-analysis of randomized clinical trials. J. Gen. Intern. Med. 35, 1849-1860 (2020).
Eriksson, J.W. et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension 52, 1030-1037 (2008).
Izaola-Jauregui, O., Primo-Martin, D., Lopez, J.J. & de Luis-Roman, D.A. The risk variant of CDKAL1 (rs7756992) impairs fasting glucose levels and insulin resistance improvements after a partial meal-replacement hypocaloric diet. Endocrinol Diabetes Nutr (Engl Ed). 68, 548-556 (2021).
Ubeda, M., Kemp, D.M. & Habener, J.F. Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. Endocrinology 145, 3023-3031 (2004).
Wei, F.Y. et al. Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat. Med. 11, 1104-1108 (2005).
Yao, Y. et al. Evaluate the effects of serum urate level on bone mineral density: a genome-wide gene-environment interaction analysis in UK Biobank cohort. Endocrine 73, 702-711 (2021).
Giri, A.K. et al. Genome wide association study of uric acid in Indian population and interaction of identified variants with type 2 diabetes. Sci. Rep. 6, 21440 (2016).
Jutabha, P., Anzai, N., Wempe, M.F., Wakui, S., Endou, H. & Sakurai, H. Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule. Nucleosides Nucleotides Nucleic Acids 30, 1302-1311 (2011).
Jing, J. et al. Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease. Sci. Rep. 8, 13184 (2018).
Dalbeth, N. et al. Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study. RMD Open 3, e000424 (2017).
Jutabha, P. et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J. Biol. Chem. 285, 35123-35132 (2010).
Tsushima, Y. et al. Uric acid secretion from adipose tissue and its increase in obesity. J. Biol. Chem. 288, 27138-27149 (2013).
Sedaghat, S. et al. Association of uric acid genetic risk score with blood pressure: the Rotterdam study. Hypertension 64, 1061-1066 (2014).
Ben Salem, C., Slim, R., Fathallah, N. & Hmouda, H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 56, 679-688 (2017).